About Us

ViroStatics was founded in 2005 by the Research Institute for Genetic and Human Therapy, USA (RIGHT) and Società Finanziaria Regione Sardegna, Italy (SFIRS). The Company has its registered office in Sassari, headquarters and laboratories in Alghero, Sardinia (Italy) and operational offices in Princeton, New Jersey (USA).

The focus of ViroStatics is on the development of novel therapeutics in the fields of chronic, life-threatening infections that both improve immune function and suppress pathogen replication. The Company's lead candidates are novel antiviral/immune protective compounds for the treatment of HIV/AIDS. ViroStatics has developed an innovative core platform to achieve its goal: a new drug class now known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs). ViroStatics has successfully established the Proof of Concept in man for this new class of antiviral/immune protective agents that it has pioneered using its two-drug first-generation AV-HALT, VS411.

AV-HALTs AntiViral-Hyperactivation Limiting Therapeutics
First-Generation AV-HALT:		Second-Generation AV-HALTs:
VS411 - a two-drug combination AV-HALT designed to establish the Proof of Concept for the new class.		Novel compounds that combine both the antiviral and hyperactivation limiting characteristics of the AV-HALT class in a single molecule.
A new class of antiviral/immune protective agents introduced by ViroStatics designed to not only reduce viral replication, but also to decrease the abnormally elevated inflammation and cellular proliferation that drive disease progression

Having successfully achieved the human Proof of Concept for AV-HALTs with VS411, ViroStatics is focused exclusively on the development of second-generation single-molecule AV-HALTs. The Company has several product candidates in development as second-generation AV-HALTs displaying pronounced dual antiviral and anti-inflammatory characteristics in a single molecule. As such, they have the potential to effectively protect the immune system from chronic hyperactivation while also reducing viral replication.

From our beginnings as a company working primarily in the HIV/AIDS space, ViroStatics has now begun to apply our learnings to other chronic infections and inflammatory diseases.

Business Strategy

ViroStatics has established in-house drug discovery programs centered around two directed chemical libraries of novel compounds which were in-licensed from the University of Siena, Italy, and from Vichem Chemie, Hungary, in 2009 and 2010, respectively.

In addition to these in-house drug discovery programs, the Company is seeking to identify and in-license compounds that have dual antiviral and anti-inflammatory characteristics yet are not currently under development for infectious disease indications.

ViroStatics plans to progress its pipeline of second-generation AV-HALTS through to Proof of Concept then seek a Biotech or Pharmaceutical partner for further development and commercialization of the products.

For more information on ViroStatics business development opportunities, please contact:
Dr. James Chafouleas, PhD
Chief Business Development Officer
j.chafouleas@virostatics.com